In a report released yesterday, Kaveri Pohlman from BTIG maintained a Hold rating on Nuvation Bio (NUVB – Research Report). The company’s shares opened today at $1.53.
Pohlman covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Genmab, and Ambrx Biopharma. According to TipRanks, Pohlman has an average return of -11.6% and a 32.50% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nuvation Bio with a $4.25 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.55 and a one-year low of $0.95. Currently, Nuvation Bio has an average volume of 1.38M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nuvation Bio (NUVB) Company Description:
Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Read More on NUVB:
